WAVE Life Sciences (WVE) Expected to Release Quarterly Earnings on Tuesday

WAVE Life Sciences (NASDAQ:WVE) will likely be issuing its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect WAVE Life Sciences to announce earnings of ($0.34) per share and revenue of $4.51 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

WAVE Life Sciences (NASDAQ:WVE) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). The business had revenue of $2.27 million for the quarter, compared to analysts’ expectations of $7.45 million. WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. On average, analysts expect WAVE Life Sciences to post ($1.12) EPS for the current fiscal year and ($1.29) EPS for the next fiscal year.

WAVE Life Sciences Trading Down 1.5%

Shares of WVE opened at $3.37 on Thursday. The stock has a 50 day moving average of $4.31 and a 200 day moving average of $5.64. The company has a market capitalization of $664.67 million, a price-to-earnings ratio of -3.09 and a beta of -1.43. WAVE Life Sciences has a 12 month low of $3.04 and a 12 month high of $21.73.

Insider Buying and Selling

In related news, Director Heidi Wagner sold 7,000 shares of WAVE Life Sciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total value of $42,070.00. Following the sale, the director owned 44,930 shares of the company’s stock, valued at approximately $270,029.30. The trade was a 13.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Adrian Rawcliffe sold 12,700 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 23,564 shares of company stock worth $132,476 in the last ninety days. 24.34% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have weighed in on WVE shares. HC Wainwright reissued a “buy” rating on shares of WAVE Life Sciences in a research report on Friday, October 2nd. JPMorgan Chase & Co. started coverage on WAVE Life Sciences in a research report on Wednesday, September 23rd. They set a “neutral” rating for the company. Mizuho lowered their target price on WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 4th. LADENBURG THALM/SH SH initiated coverage on shares of WAVE Life Sciences in a report on Thursday, October 1st. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Zacks Research lowered shares of WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, WAVE Life Sciences has an average rating of “Moderate Buy” and a consensus price target of $21.53.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.